Title : Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.

Pub. Date : 2021 May

PMID : 33991465






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PAI-1-targeted fibrinolytic therapy (PAI-1-TFT) is designed to decrease the therapeutic dose of tPA and uPA, attenuating the risk of bleeding and other complications. Tetradecanoylphorbol Acetate serpin family E member 1 Homo sapiens
2 PAI-1-targeted fibrinolytic therapy (PAI-1-TFT) is designed to decrease the therapeutic dose of tPA and uPA, attenuating the risk of bleeding and other complications. Tetradecanoylphorbol Acetate serpin family E member 1 Homo sapiens
3 PAI-1-TFT with DSP (2.0 mg/kg) converted ineffective doses of single chain (sc) tPA (72.5 microg/kg) and scuPA (62.5 microg/kg) into effective ones in chemically induced pleural injury. Tetradecanoylphorbol Acetate serpin family E member 1 Homo sapiens